Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5723982 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL5723978 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| Formic Acid SCHEMBL28194380 | 0.95 | ALDH1A1 (0.44) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL8758764 | 0.93 | DPP8 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTOPRK1 | |
| SCHEMBL5724018 | 0.92 | SMN1; SMN2 (0.51) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL5723654 | 0.90 | TDP1 (0.52) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6104418 | 0.89 | GBA1 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6102402 | 0.89 | GBA1 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6104410 | 0.89 | GBA1 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A | |
| SCHEMBL6102412 | 0.89 | GBA1 (0.48) | ALDH1A1LMNASMN1; SMN2MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485647-B2 | 2-aminoquinoline derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MSD K.K. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1630162-A1 | 2-AMINOQUINOLINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-03-01 | — | — | EP | disclosed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| EP-0774465-A1 | Penem derivatives and antimicrobial agents containing the same | SUNTORY LIMITED (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0161541-B1 | 6-[1-Hydroxyethyl]-2-SR8-1-methyl-1-carba-dethiapen-2-em-3-carboxylic acids | MERCK & CO. INC. (US) | 1990-12-12 | — | — | EP | disclosed |
| US-4696923-A | THIENAMYCIN ANTIBIOTICS, BACTERICIDES | MERCK & CO., INC. (US) | 1987-09-29 | — | — | US | disclosed |
| EP-0161541-A1 | 6-[1-Hydroxyethyl]-2-SR8-1-methyl-1-carba-dethiapen-2-em-3-carboxylic acids | MERCK & CO. INC. (US) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287340-A1 | 2-Aminoquinoline derivatives | MCHR2, MC2R, MCHR1 | ALDH1A1 1932/4885LMNA 2760/4885SMN1; SMN2 2295/4885 |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | ALDH1A1 1862/4885LMNA 3637/4885SMN1; SMN2 3757/4885 |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | ALDH1A1 518/4885LMNA 2166/4885SMN1; SMN2 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.